Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
February 02 2022 - 7:00AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company
discovering and developing allogeneic gamma delta CAR T cell
therapies for cancer and other diseases, today announced that Chen
Schor, President and Chief Executive Officer, will participate in a
fireside chat at the Guggenheim 2022 Oncology Conference taking
place virtually on February 9-11, 2022.
Details of the event are as follows:
Date: Wednesday, February 9, 2022 Time: 11:30 am ET
A live audio webcast of the fireside chat can be accessed on the
Investors section of Adicet Bio’s website at
https://investor.adicetbio.com. An archived replay will be
available for 30 days following the presentation.
About Adicet Bio, Inc.
Adicet Bio, Inc. is a biotechnology company discovering and
developing allogeneic gamma delta T cell therapies for cancer and
other diseases. Adicet is advancing a pipeline of “off-the-shelf”
gamma delta T cells, engineered with chimeric antigen receptors and
T cell receptor-like antibodies to enhance selective tumor
targeting, facilitate innate and adaptive anti-tumor immune
response, and improve persistence for durable activity in
patients.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220201006166/en/
Adicet Bio., Inc. Investor Contacts Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite Stern Investor Relations, Inc. 212-362-1200
janhavi.mohite@sternir.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Jul 2023 to Jul 2024